Larimar Therapeutics is a cash-burning, sub-floor-quality biotech that triggered a death-cross technical block and carries elevated, justified short interest, though the two most recent quarters both beat estimates and institutions and insiders have both been buying.
Thesis pillars
- Cash Burn Quality Below Floor→Stable
- Death Cross Technical Block→Stable
- Elevated Justified Short Interest↑Improving
- +1 more pillar — see the Why tab for full reasoning
Larimar Therapeutics, Inc. (LRMR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum.
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a subcutaneously administered fusion protein designed to deliver frataxin to the mitochondria of patients with Friedreich's ataxia, using its cell-penetrating peptide platform. The company has... Read more
Sell if holding. Engine safety override at $3.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-10Recent Developments — Larimar Therapeutics, Inc.
Latest news
- NEWS Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate — benzinga Aug 4, 2026 positive
Generated 2026-08-05T10:39:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelinenomlabofusp10-K Item 1A: 'our business is currently wholly dependent on our successful clinical development, regulatory approval and commercialization of nomlabofusp'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.61. Score 4.6/10, moderate confidence.
Take-profit target: $4.37 (+12.9% upside). Prior stop was $3.61. Stop-loss: $3.61.
Concentration risk — Pipeline: nomlabofusp; DATA_ISSUE: analyst_target_implausible (raw $14.30 vs price $3.87 — ratio 3.7×). Rejected, falling back to technical TP.; Quality below floor (1.9 < 4.0).
Larimar Therapeutics, Inc. trades at a P/E of N/A (forward -3.8). TrendMatrix value score: 5.0/10. Verdict: Sell.
17 analysts cover LRMR with a consensus score of 4.4/5. Average price target: $14.
What does Larimar Therapeutics, Inc. do?Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a subcutaneously administered...
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a subcutaneously administered fusion protein designed to deliver frataxin to the mitochondria of patients with Friedreich's ataxia, using its cell-penetrating peptide platform. The company has no commercial revenue and reported $136.9 million in cash and marketable securities as of December 31, 2025, expected to fund operations into the second quarter of 2027 alongside a February 2026 offering.